Drug Profile
[18F]FP R01 MG F2
Alternative Names: [18F]FP R01 MG F2Latest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator Stanford University
- Developer Pliant Therapeutics; Stanford University
- Class Diagnostic agents; Imaging agents; Radiopharmaceutical diagnostics
- Mechanism of Action Positron-emission tomography enhancers; Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Idiopathic pulmonary fibrosis
Most Recent Events
- 28 Jul 2020 No recent reports of development identified for phase-I development in Idiopathic-pulmonary-fibrosis(Diagnosis) in USA
- 15 Oct 2019 Pliant Therapeutics plans a phase IIa trial for Idiopathic pulmonary fibrosis (Diagnosis) using PLN 74809
- 08 Jun 2017 Phase-I clinical trials in Idiopathic pulmonary fibrosis (Diagnosis) in USA (unspecified route) (NCT03183570)